| Similar Articles |
|---|
 |
BusinessWeek
September 5, 2005
Gene G. Marcial |
AtheroGenics May Be A Buyout AtheroGenics is one of the more attractive acquisition candidates of Merck or Pfizer.   |
The Motley Fool
April 1, 2005
Rich Duprey |
The Inside Track to Big Profits Senior management, the so-called corporate "insider," has intimate knowledge of its businesses' operations. Insider transactions can signal to investors the right time to make big profits. Knowing which signals to watch and which to ignore is the key. |
The Motley Fool
August 30, 2005
Charly Travers |
A Drug to Make Hearts Happy? Atherogenics has a potential blockbuster in a drug that could reverse the clogging of arteries. Investors, take note. |
The Motley Fool
June 7, 2005
Tom Taulli |
ValueAct's "Tough Love" Letter ValueAct is a fund that doesn't sit around. If management falters, it agitates for change. |
The Motley Fool
October 24, 2006
Brian Lawler |
Playing the AtheroGenics Waiting Game The results of phase 3 trials for the company's atherosclerosis drug will determine AtheroGenics' future. Investors, take note. |
The Motley Fool
January 27, 2004
David Nierengarten |
Pfizer's Next Target? Esperion, swallowed by Pfizer last year, shares many similarities with Atherogenics. Investors in the latter, however, should not count on being acquired any time soon by a big pharmaceutical company. |
The Motley Fool
October 2, 2007
Tom Taulli |
Acxiom of Shareholder Evil ValueAct Capital Partners said it plans to abandon its buyout of Acxiom, causing shares of the information-based product development company to tumble. |
The Motley Fool
February 26, 2007
Brian Lawler |
Waiting on AtheroGenics The results might be positive for this pharma, but don't bet on it. Investors, take note. |
The Motley Fool
January 25, 2006
Rick Casterline |
Is BABY Born Again? Natus Medical's 200% growth may be just the beginning. Between its international and domestic efforts, the company is firing on all cylinders. Investors, take note. |
The Motley Fool
July 22, 2005
Rich Smith |
An Acxiomatic Bargain Assuming Acxiom feels it paid the right price for Digital Impact, it's not likely to agree to a buyout offer of anything less than three times Acxiom's own sales: $3.6 billion, or roughly $41 a share. |
The Motley Fool
January 11, 2007
Matt Koppenheffer |
The 5-Sigma Report A look at the stocks that saw serious volatility last week. Semiconductor Manufacturing International... Herbalife... New York & Company... Atherogenics... Hot Topic... |
The Motley Fool
March 16, 2006
Rich Duprey |
Chiron's Shareholder Revolt Hedge funds oppose the biotech's buyout by pharmaceutical giant Novartis. Investors, take note. |
The Motley Fool
May 16, 2006
Rich Smith |
Foolish Forecast: Is Acxiom Tilting? The data collator reports its fiscal fourth-quarter and full-year 2006 numbers tomorrow after close of market. Investors, here's what you need to know to put them in context. |
The Motley Fool
March 20, 2007
Brian Lawler |
Heart Attack at AtheroGenics Shares of AtheroGenics drop after negative phase 3 trial results. |
The Motley Fool
March 28, 2005
Rich Smith |
Acxiom Collects Data Collector The the data-brokering company bids to make its third acquisition in the past six months. In total, and subject to approval by Digital Impact's shareholders, Acxiom will pay $129 million to acquire 36.9 million shares. |
The Motley Fool
June 4, 2007
Brian Lawler |
Is AtheroGenics Grasping at Straws? The pharmaceutical announces the path forward for its lead drug. Investors, take note. |
BusinessWeek
December 13, 2004
Justin Hibbard |
Where Others See Trouble... Jeffrey Ubben, managing director of the San Francisco hedge fund ValueAct Capital Partners, is finding bargains in companies with accounting snafus. |
The Motley Fool
March 16, 2007
Tim Hanson |
Natus Medical vs. Under Armour: Natus Medical In honor of the annual NCAA College Basketball Tournament, a.k.a. March Madness -- here is "Stock Madness 2007." Natus Medical may be small, but it can bring the noise for investors. |
The Motley Fool
July 25, 2006
Rich Smith |
Foolish Forecast: Acxiom's Turn The data collator reports its fiscal first-quarter 2007 earnings tomorrow after close of market. Investors, here's a review of the company's recent numbers. |
The Motley Fool
May 1, 2006
Rich Smith |
Foolish Forecast: Natus Medical's Prognosis With a better than 130% rise in stock price over the last year, this young medical device maker is looking quite healthy. Just to be safe, though, let's take a look at its latest earnings report. |
The Motley Fool
July 30, 2007
Brian Lawler |
AtheroGenics Follows a New Route AtheroGenics gives more details on the path forward for its lead drug. The drugmaker is trading at a low $70 million valuation, but investors who buy into shares today shouldn't get their hopes up for the outcome. |
The Motley Fool
January 3, 2006
Tom Taulli |
Bet On Brooks Automation? Brooks Automation may look like a bad investment, but the smart money says otherwise. |
The Motley Fool
March 28, 2007
Brian Lawler |
AtheroGenics Splices the Data Shares of AtheroGenics will continue to be volatile in the next couple of months as investors await the probable discontinuation of the company's partnership with AstraZeneca. |
